Authors

• Michael C. Brumm (ORCID: https://orcid.org/0000-0002-3173-9989)
• Ben Shifflett (ORCID: https://orcid.org/0000-0002-6758-1220)
• Luis Concha‐Marambio (ORCID: https://orcid.org/0000-0002-9454-8389)
• Yihua Ma (ORCID: https://orcid.org/0000-0002-5664-8178)
• David G. Coughlin (ORCID: https://orcid.org/0000-0003-4111-0102)
• Kathleen L. Poston (ORCID: https://orcid.org/0000-0003-3424-7143)
• Douglas R Galasko (ORCID: https://orcid.org/0000-0001-6195-3241)
• Andrew D. Siderowf (ORCID: https://orcid.org/0000-0002-1750-7698)
• Carly M. Farris (ORCID: https://orcid.org/0000-0002-8277-8531)
• Brit Mollenhauer (ORCID: https://orcid.org/0000-0001-8437-3645)
• Claudio Soto
• Steven D. Edland (ORCID: https://orcid.org/0000-0002-1153-7335)
• Kenneth Marek (ORCID: https://orcid.org/0000-0002-4197-5627)

Institutions

• University of Iowa (US)
• University of California San Diego (US)
• Alzheimer’s Disease Neuroimaging Initiative (US)
• Institute for Neurodegenerative Disorders (US)
• Amprion (United States) (US)
• Universitätsmedizin Göttingen (DE)
• Paracelsus Elena Klinik Kassel (DE)
• University of Pennsylvania (US)
• Stanford University (US)

Publication Details

Journal

Neurology

Published

2025-02-06

DOI

https://doi.org/10.1212/wnl.0000000000210279

Citations

21

Primary Topic

Parkinson's Disease Mechanisms and Treatments

Type

article

Field-Weighted Citation Impact

29.17

Funders

• Michael J. Fox Foundation for Parkinson's Research
• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Sanofi
• Biogen
• Teva Pharmaceutical Industries
• Celgene
• Jazz Pharmaceuticals
• Neurocrine Biosciences
• Verily Life Sciences
• Voyager Therapeutics
• Servier
• H. Lundbeck A/S
• Sun Pharma
• Genentech
• Allergan
• Avid Radiopharmaceuticals